Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts rate Innate Pharma “Moderate Buy”: Five of six analysts recommend buying the stock, while one has issued a sell rating. The average 12-month price target is $6.67.
• Several firms recently raised their views on IPHA, including HC Wainwright to a $7 target and BTIG Research to a $9 target; Leerink Partners also upgraded the stock to “outperform.”
• IPHA opened at $2.08, with a 12-month range of $1.17 to $2.71. Institutional ownership remains limited at 0.16% of outstanding shares.

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.6667.

IPHA has been the topic of a number of analyst reports. Leerink Partners raised Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. HC Wainwright upped their price objective on shares of Innate Pharma from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, August 10th. BTIG Research raised their target price on shares of Innate Pharma from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. UBS Group restated a "buy" rating on shares of Innate Pharma in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, June 26th.

Institutional Trading of Innate Pharma

A number of hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Innate Pharma in the fourth quarter worth $162,000. Millennium Management LLC acquired a new position in Innate Pharma during the fourth quarter valued at $36,000. Finally, OLD Mission Capital LLC acquired a new position in Innate Pharma during the fourth quarter valued at $50,000. Hedge funds and other institutional investors own 0.16% of the company's stock.

Innate Pharma Stock Down 1.4%

Shares of NASDAQ IPHA opened at $2.08 on Friday. Innate Pharma has a 12 month low of $1.17 and a 12 month high of $2.71. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $1.73.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source